Verano Holdings (VRNO) Operating Leases (2021 - 2026)
Verano Holdings' (VRNO) quarterly Operating Leases came in at $101.4 million in Q1 2026, down 6.18% year-on-year from $108.1 million in Q1 2025, and up 11.33% on a QoQ basis from $91.1 million in Q4 2025.
Verano Holdings (VRNO) Operating Leases (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Operating Leases data on file, last reported at $101.4 million in Q1 2026.
- On a quarterly basis, Operating Leases fell 6.18% year-over-year to $101.4 million in Q1 2026; TTM through Mar 2026 was $101.4 million, a 6.18% decrease from a year earlier, with the FY2025 full-year figure at $91.1 million, down 6.94% from the prior year.
- Operating Leases for Q1 2026 stood at $101.4 million, up from $91.1 million in the prior quarter.
- Over the last five years, Operating Leases for VRNO reached as high as $108.1 million in Q1 2025 and fell as low as $71.8 million in Q3 2022.
- Historically, Operating Leases has averaged $88.8 million across 5 years, with a median of $87.8 million in 2023.
- Across the five-year window, Operating Leases jumped 35.28% in 2022 and decreased 6.94% in 2025, its largest moves.
- Year by year, Operating Leases stood at $76.9 million in 2022, then grew by 13.72% to $87.4 million in 2023, then advanced by 12.0% to $97.9 million in 2024, then declined by 6.94% to $91.1 million in 2025, then climbed by 11.33% to $101.4 million in 2026.
- Per Business Quant data, the three most recent Operating Leases figures were $101.4 million in Q1 2026, $91.1 million in Q4 2025, and $92.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 101.41 Mn |
| Dec 31, 2025 | 91.09 Mn |
| Sep 30, 2025 | 92.95 Mn |
| Jun 30, 2025 | 94.29 Mn |
| Mar 31, 2025 | 108.08 Mn |
| Dec 31, 2024 | 97.88 Mn |
| Sep 30, 2024 | 90.80 Mn |
| Jun 30, 2024 | 86.78 Mn |
| Mar 31, 2024 | 86.37 Mn |
| Dec 31, 2023 | 87.40 Mn |
| Sep 30, 2023 | 85.62 Mn |
| Jun 30, 2023 | 88.30 Mn |
| Mar 31, 2023 | 86.83 Mn |
| Dec 31, 2022 | 76.85 Mn |
| Sep 30, 2022 | 71.81 Mn |
| Jun 30, 2022 | 74.08 Mn |
| Dec 31, 2021 | 56.81 Mn |